In a featured global webinar, Laura presented an extensive preclinical trial conducted in collaboration with Boehringer Ingelheim, reflecting over 4 years of dedicated research. This study focused on preventing aortic aneurysm formation by targeting MMP13 inhibition.

The approach involved testing a new compound in vivo and employing innovative screening methods, such as echocardiography, to accurately detect and monitor aneurysm progression. The preclinical results highlighted the compound's potential in effectively managing aneurysm development.

Laura presented these findings during the webinar, engaging with international experts to discuss the implications and advancements stemming from the research. This case study exemplifies our commitment to advancing drug development and showcases our expertise in pioneering preclinical trial methodologies.